J Cancer
2018; 9(1):54-63.
doi:10.7150/jca.22190 This issueCite
Research Paper
Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy
1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P.R China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R China. *Ronald Wihal Oei and Lu-Lu Ye made equal contribution to this work.
✉ Corresponding author: Professor Hongmei Ying; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 200032, P.R China; Telephone: +86-21-64175590; Fax: +86-21-6417477; E-mail: yinghongmei2013com
Citation:
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J Cancer 2018; 9(1):54-63. doi:10.7150/jca.22190. https://www.jcancer.org/v09p0054.htm
Objective:To analyze the prognostic value of pre-treatment serum lactate dehydrogenase (SLDH) level in patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
Methods:From January 2010 to March 2013, 427 eligible patients were reviewed. Pre-treatment SLDH level was measured within 2 weeks prior to treatment. Receiver operating characteristic (ROC) curve analysis was performed to select the optimal cutoff point. The impact of pre-treatment SLDH on overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were analyzed using Kaplan-Meier method and Cox proportional hazards model. Further propensity score matching was carried out to adjust bias.
Results:The optimal cutoff point of 168.5 IU/L was selected based on ROC curve analysis. Multivariate analysis showed that high pre-treatment SLDH level was an independent prognostic factor for OS (P=0.001), PFS (P=0.004) and DMFS (P=0.001). After propensity score matching was performed, it remained to be significantly associated with poor OS (P=0.009), PFS (P=0.015) and DMFS (P=0.008) in the adjusted model.
Conclusion:High pre-treatment SLDH level predicts poor survival in patients with NPC treated with IMRT-based therapy. As a routinely performed biomarker, pre-treatment SLDH can be utilized in combination with current Tumor-Node-Metastasis staging to predict survival and to plan a personalized treatment in these patients.
Oei, R.W., Ye, L., Kong, F., Du, C., Zhai, R., Xu, T., Shen, C., Wang, X., He, X., Kong, L., Hu, C., Ying, H. (2018). Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. Journal of Cancer, 9(1), 54-63. https://doi.org/10.7150/jca.22190.
ACS
Oei, R.W.; Ye, L.; Kong, F.; Du, C.; Zhai, R.; Xu, T.; Shen, C.; Wang, X.; He, X.; Kong, L.; Hu, C.; Ying, H. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J. Cancer 2018, 9 (1), 54-63. DOI: 10.7150/jca.22190.
NLM
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J Cancer 2018; 9(1):54-63. doi:10.7150/jca.22190. https://www.jcancer.org/v09p0054.htm
CSE
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. 2018. Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. J Cancer. 9(1):54-63.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.